Artificial Pancreas Device System (APDS) Market Growth Trends Highlighted until 2024 Including Global Leading Players Analysis such as Medtronic, Medtrum, Tandem Diabetes Care, Inc., Johnson & Johnson, Beta Bionics, Bigfoot Biomedical

Administering insulin on daily basis is cumbersome for type 1 diabetes (T1D) patients in a busy lifestyle. While devices such as insulin pumps, pens, and jet injectors have made living with diabetes less stressful by ridding users of relatively painful insulin delivering devices such as needles and syringes. Juvenile Diabetes Research Foundation (JDRF) is working in collaboration with many industry players such as Medtronic, Inc., Johnson & Johnson, and Tandem Diabetes Care, Inc. to develop innovative insulin and glucose monitoring systems/devices.

Ask for Sample Copy of Research@ https://www.coherentmarketinsights.com/insight/request-sample/79

Market Dynamics

The artificial pancreas device system (APDS) market growth would be mainly driven by increasing adoption of the highly useful systems the large base of diabetes type 1 patients, further supplemented by ever increasing incidence of type 1 diabetes. According to the World Health Organization (WHO), number of diabetes patients worldwide increased from 108 million in 1980 to 422 million in 2014. According to Juvenile Diabetes Research Foundation (JDRF), there were around 1.5 million type 1 diabetics worldwide in 2015. JDRF funds research in diabetes 1 and the non-profit organization expected the first artificial pancreas to be commercialized in 2017. According to the Center for Disease Control and Prevention (CDC), type 1 diabetes accounts for around 5% of the total diagnosed diabetes cases in adults in the U.S. Developed regions are expected to dominate the artificial pancreas device system (APDS) market size, as these regions are early adopters of disruptive technologies. With the introduction of this technology, market for insulin pens and injectors is expected to be impacted negatively.

The global artificial pancreas device system (APDS) market was valued at US$ 64.0 million in 2015 and is expected to witness a moderate CAGR of 18.6% during the forecast period (2016 – 2024).

Market Key Players

Key companies covered as a part of this study include Medtronic, Medtrum, Tandem Diabetes Care, Inc., Johnson & Johnson, Beta Bionics, Bigfoot Biomedical, and Insulet Corporation

Download PDF Brochure of This Business Report@ https://www.coherentmarketinsights.com/insight/request-pdf/79

Technological advancements to drive growth of the global artificial pancreas device system (APDS) market

In 2016, the U.S. FDA approved a hybrid closed-loop artificial pancreas device system (APDS) MiniMed 670G which is an automated system. The continuous glucose monitor in the system automatically sends signals to the insulin pump to deliver insulin when the glucose level in body goes beyond the acceptable limit. Thus, there is no need for the user to stimulate the release of insulin every time the glucose level is abnormal. This provide the user freedom to perform his/her daily activities. Such advancement in T1D management is expected to be highly preferred by the users and medical community, leading to higher advocacy to use this device especially among the patient group using insulin pumps. Moreover, in mid-2018, a study will test a bihormonal “bionic pancreas” system at the Massachusetts General Hospital (Boston) and Boston University. This would further fuel the artificial pancreas device system (APDS) market growth and attract more investments.

Strategic collaborations fostering artificial pancreas device system (APDS) market growth

There were over 20 projects undertaken by the industry payers in 2015 with respect to development of artificial pancreas device system (APDS). Bigfoot Biomedical acquired Asante’s FDA approved Snap insulin pump technology in 2015 and at the same time signed a development agreement with Dexcom to integrate Dexcom’s CGM in its under development artificial pancreas device system (APDS). Dexcom is in collaboration with many other market players such as Insulet Corporation, Animas Corporation, and International Diabetes Closed Loop wherein, these companies would be incorporating Dexcom’s CGM in their artificial pancreas device system (APDS). Such collaborations are expected to expedite market entry for new artificial pancreas device system (APDS)s and thus drive the growth of artificial pancreas device system (APDS) market.

Request For Customization of Research Report@ https://www.coherentmarketinsights.com/insight/request-customization/79

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.